105 related articles for article (PubMed ID: 12695349)
1. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.
Margolis JM; Obach RS
Drug Metab Dispos; 2003 May; 31(5):606-11. PubMed ID: 12695349
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
Obach RS
Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
[TBL] [Abstract][Full Text] [Related]
3. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
4. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
5. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
6. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
7. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
8. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
Obach RS
Drug Metab Dispos; 1997 Dec; 25(12):1359-69. PubMed ID: 9394025
[TBL] [Abstract][Full Text] [Related]
9. Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6.
Umeda S; Harakawa N; Yamamoto M; Ueno K
Biol Pharm Bull; 2005 Feb; 28(2):212-6. PubMed ID: 15684471
[TBL] [Abstract][Full Text] [Related]
10. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
11. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
Dalmadi B; Leibinger J; Szeberényi S; Borbás T; Farkas S; Szombathelyi Z; Tihanyi K
Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
[TBL] [Abstract][Full Text] [Related]
12. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
13. Impact of impurities on IC50 values of P450 inhibitors.
Huang Z
Drug Metab Lett; 2011 Aug; 5(3):156-62. PubMed ID: 21722088
[TBL] [Abstract][Full Text] [Related]
14. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
15. Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain.
Niwa T; Okada K; Hiroi T; Imaoka S; Narimatsu S; Funae Y
Biol Pharm Bull; 2008 Mar; 31(3):348-51. PubMed ID: 18310890
[TBL] [Abstract][Full Text] [Related]
16. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
17. Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum, Is a CYP2D6 inhibitor of human, monkey, and dog isoforms.
Sun J; Peng Y; Wu H; Zhang X; Zhong Y; Xiao Y; Zhang F; Qi H; Shang L; Zhu J; Sun Y; Liu K; Liu J; A J; Ho RJ; Wang G
Drug Metab Dispos; 2015 May; 43(5):713-24. PubMed ID: 25681130
[TBL] [Abstract][Full Text] [Related]
18. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
Brown HS; Chadwick A; Houston JB
Drug Metab Dispos; 2007 Nov; 35(11):2119-26. PubMed ID: 17724064
[TBL] [Abstract][Full Text] [Related]
19. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction.
Obach RS
Drug Metab Dispos; 2001 Jul; 29(7):1057-67. PubMed ID: 11408374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
